xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06005493</url>
    </required_header>
    <id_info>
      <org_study_id>D9750C00001</org_study_id>
      <secondary_id>2023-000154-20</secondary_id>
      <nct_id>NCT06005493</nct_id>
    </id_info>
    <brief_title>Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors</brief_title>
    <official_title>A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>AstraZeneca</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>AstraZeneca</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This research is designed to determine if experimental treatment with AZD5863, a T&#xD;
        cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe,&#xD;
        tolerable and has anti-cancer activity in patients with advanced solid tumors.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This is a first-time in human, modular Phase I/II, open-label multicentre study of AZD5863&#xD;
        monotherapy administered intravenously (Module 1), or AZD5863 monotherapy administered&#xD;
        subcutaneously (Module 2) in patients with advanced or metastatic solid tumors. Each module&#xD;
        contains dose-escalation (Part A) and dose-expansion (Part B).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">July 11, 2023</start_date>
    <completion_date type="Anticipated">December 11, 2026</completion_date>
    <primary_completion_date type="Anticipated">December 11, 2026</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Sequential Assignment</intervention_model>
      <intervention_model_description>The study consists of individual modules each evaluating the safety and tolerability of AZD5863 dosed as monotherapy:&#xD;
  Module 1: AZD5863 intravenous administration&#xD;
  Module 2: AZD5863 subcutaneous administration&#xD;
  Modules 1 and 2 each consist of two parts: Part A, Dose Escalation and Part B, Dose Expansion.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>The number of patients with adverse events</measure>
      <time_frame>From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy</time_frame>
      <description>Number of patients with adverse events by system organ class and preferred term</description>
    </primary_outcome>
    <primary_outcome>
      <measure>The number of patients with adverse events of special interest</measure>
      <time_frame>From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy</time_frame>
      <description>Number of patients with adverse events of special interest by system organ class and preferred term</description>
    </primary_outcome>
    <primary_outcome>
      <measure>The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.</measure>
      <time_frame>From first dose of study drug until the end of Cycle 1</time_frame>
      <description>A DLT is a toxicity as defined in the protocol that occurs from the first dose of study drug up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>The number of patients with serious adverse events</measure>
      <time_frame>From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy</time_frame>
      <description>Number of patients with serious adverse events by system organ class and preferred term</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Objective Response Rate (ORR)</measure>
      <time_frame>From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)</time_frame>
      <description>The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose expansion only.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Objective Response Rate (ORR)</measure>
      <time_frame>From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)</time_frame>
      <description>The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose escalation only.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Control Rate (DCR)</measure>
      <time_frame>From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)</time_frame>
      <description>Percentage of patients with confirmed complete or partial response or having stable disease maintained for &gt;= 11 weeks from first dose, according to response criteria in solid tumours (RECIST 1.1).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Duration of response (DoR)</measure>
      <time_frame>From the first documented response to progressive disease or death in the absence of disease progression (approx. 2 years)</time_frame>
      <description>The time from the date of first response until date of disease progression or death in the absence of disease progression, according to response criteria in solid tumours (RECIST 1.1).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Progression free Survival (PFS)</measure>
      <time_frame>From the start of study treatment/date of randomization to progressive disease or death in the absence of disease progression (approx. 2 years)</time_frame>
      <description>The time from the start of study treatment/date of randomization until RECIST 1.1 defined disease progression or death in the absence of disease progression.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall Survival (OS)</measure>
      <time_frame>From the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)</time_frame>
      <description>The time from the start of study treatment/date of randomization until death due to any cause.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics of AZD5863: Maximum plasma concentration of the study drug (Cmax)</measure>
      <time_frame>From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)</time_frame>
      <description>Maximum observed plasma concentration of the study drug</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics of AZD5863: Area Under the concentration-time curve (AUC)</measure>
      <time_frame>From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)</time_frame>
      <description>Area under the plasma concentration-time curve</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics of AZD5863: Clearance</measure>
      <time_frame>From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)</time_frame>
      <description>A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics of AZD5863: Terminal elimination half-life (t 1/2)</measure>
      <time_frame>From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)</time_frame>
      <description>Terminal elimination half life.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Immunogenicity of AZD5863</measure>
      <time_frame>From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)</time_frame>
      <description>The number and percentage of participants who develop anti-drug antibodies (ADAs) measured in serum</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863</measure>
      <time_frame>From time of Informed consent, at predefined intervals (including screening, on-treatment or end of treatment) throughout the study (over approx. 2 years)</time_frame>
      <description>Measure CLDN18.2 expression (IHC) in baseline and/or on-treatment tumor biopsies and correlate with clinical outcome</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">200</enrollment>
    <condition>Gastric Cancer</condition>
    <condition>Gastro-esophageal Junction Cancer</condition>
    <condition>Pancreatic Ductal Adenocarcinoma</condition>
    <condition>Esophageal Adenocarcinoma</condition>
    <arm_group>
      <arm_group_label>Module 1: AZD5863 Monotherapy Intravenous (IV)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Module 1: AZD5863 Intravenous (IV) Monotherapy</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Module 2: AZD5863 Monotherapy Subcutaneous (SC)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Module 2: AZD5863 Subcutaneous (SC) Monotherapy</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>AZD5863</intervention_name>
      <description>T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells</description>
      <arm_group_label>Module 1: AZD5863 Monotherapy Intravenous (IV)</arm_group_label>
      <arm_group_label>Module 2: AZD5863 Monotherapy Subcutaneous (SC)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Key Inclusion Criteria:&#xD;
  &#xD;
            -  Age ≥ 18 at the time of signing the informed consent&#xD;
  &#xD;
            -  Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal&#xD;
               junction, esophagus, or pancreas&#xD;
  &#xD;
            -  Must have at least one measurable lesion according to Response Evaluation Criteria in&#xD;
               Solid Tumors (RECIST) v1.1&#xD;
  &#xD;
            -  Must show positive CLDN18.2 expression in tumor cells as determined by central&#xD;
               immunohistochemistry (IHC)&#xD;
  &#xD;
            -  Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening&#xD;
  &#xD;
            -  Predicted life expectancy of ≥ 12 weeks&#xD;
  &#xD;
            -  Adequate organ and bone marrow function measured within 28 days prior to first dose as&#xD;
               defined by the protocol&#xD;
  &#xD;
            -  Contraceptive use by men or women should be consistent with local regulations, as&#xD;
               defined by the protocol&#xD;
  &#xD;
            -  Must have received at least one prior line of systemic therapy in the&#xD;
               advanced/metastatic setting&#xD;
  &#xD;
          Key Exclusion Criteria:&#xD;
  &#xD;
            -  Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for&#xD;
               Adverse Events (CTCAE) Grade ≥ 2 except for those defined by the protocol&#xD;
  &#xD;
            -  Participant experienced unacceptable cytokine release syndrome (CRS) or Immune&#xD;
               Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE)&#xD;
               or chimeric antigen receptor T (CAR-T) cell therapy&#xD;
  &#xD;
            -  Active or prior documented autoimmune or inflammatory disorders within 3 years of&#xD;
               start of treatment&#xD;
  &#xD;
            -  central nervous system (CNS) metastases or CNS pathology, as defined by the protocol,&#xD;
               within 3 months prior to consent&#xD;
  &#xD;
            -  Infectious disease including active human immunodeficiency virus (HIV), active&#xD;
               hepatitis B/C, uncontrolled active systemic fungal, bacterial or other infection&#xD;
  &#xD;
            -  Cardiac conditions as defined by the protocol&#xD;
  &#xD;
            -  History of thromboembolic event within the past 3 months prior to the scheduled first&#xD;
               dose of study intervention&#xD;
  &#xD;
            -  Participant requires chronic immunosuppressive therapy&#xD;
  &#xD;
            -  Participants on anticoagulation therapy&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>AstraZeneca Clinical Study Information Center</last_name>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Jacksonville</city>
          <state>Florida</state>
          <zip>32224</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Rochester</city>
          <state>Minnesota</state>
          <zip>55905</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>New York</city>
          <state>New York</state>
          <zip>10065</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Beijing</city>
          <zip>100142</zip>
          <country>China</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Beijing</city>
          <zip>101199</zip>
          <country>China</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Shandong</city>
          <country>China</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Chuo-ku</city>
          <zip>104-0045</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Kashiwa</city>
          <zip>227-8577</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Koto-ku</city>
          <zip>135-8550</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Seodaemun-gu</city>
          <zip>03722</zip>
          <country>Korea, Republic of</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Seoul</city>
          <zip>03080</zip>
          <country>Korea, Republic of</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Seoul</city>
          <zip>05505</zip>
          <country>Korea, Republic of</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Seoul</city>
          <zip>06351</zip>
          <country>Korea, Republic of</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Amsterdam</city>
          <zip>1081 HV</zip>
          <country>Netherlands</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Groningen</city>
          <zip>9713 GZ</zip>
          <country>Netherlands</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Kaohsiung</city>
          <zip>80756</zip>
          <country>Taiwan</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Tainan</city>
          <zip>704</zip>
          <country>Taiwan</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Taoyuan</city>
          <zip>333</zip>
          <country>Taiwan</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Dundee</city>
          <zip>DD1 9SY</zip>
          <country>United Kingdom</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>London</city>
          <zip>E1 1BB</zip>
          <country>United Kingdom</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Oxford</city>
          <zip>OX3 7LE</zip>
          <country>United Kingdom</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location>
      <facility>
        <name>Research Site</name>
        <address>
          <city>Wirral</city>
          <zip>CH63 4JY</zip>
          <country>United Kingdom</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
    </location>
    <location_countries>
      <country>China</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
      <country>United States</country>
    </location_countries>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>June 16, 2023</study_first_submitted>
    <study_first_submitted_qc>August 17, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 22, 2023</study_first_posted>
    <last_update_submitted>September 14, 2023</last_update_submitted>
    <last_update_submitted_qc>September 14, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 15, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>CLDN18.2 / Claudin 18.2</keyword>
    <keyword>CD3</keyword>
    <keyword>T cell-engaging bi-specific antibody</keyword>
    <keyword>Gastric cancer</keyword>
    <keyword>Gastro-esophageal junction cancer</keyword>
    <keyword>Pancreatic ductal adenocarcinoma</keyword>
    <keyword>Solid tumors</keyword>
    <keyword>AZD5863</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Adenocarcinoma</mesh_term>
      <mesh_term>Stomach Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure&#xD;
  &quot;Yes&quot;, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
      <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
      <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.</ipd_access_criteria>
      <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06005493
  org study id: D9750C00001
  secondary id: 2023-000154-20
  nct id: NCT06005493
  lead sponsor: 
  has dmc: No
  is fda regulated drug: Yes
  is fda regulated device: No
  This research is designed to determine if experimental treatment with AZD5863, a T
        cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe,
        tolerable and has anti-cancer activity in patients with advanced solid tumors.
  This is a first-time in human, modular Phase I/II, open-label multicentre study of AZD5863
        monotherapy administered intravenously (Module 1), or AZD5863 monotherapy administered
        subcutaneously (Module 2) in patients with advanced or metastatic solid tumors. Each module
        contains dose-escalation (Part A) and dose-expansion (Part B).
  allocation: Randomized
  intervention model: Sequential Assignment
  intervention model description: The study consists of individual modules each evaluating the safety and tolerability of AZD5863 dosed as monotherapy:
  Module 1: AZD5863 intravenous administration
  Module 2: AZD5863 subcutaneous administration
  Modules 1 and 2 each consist of two parts: Part A, Dose Escalation and Part B, Dose Expansion.
  primary purpose: Treatment
  masking: None (Open Label)
  measure: The number of patients with adverse events
  time frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
  description: Number of patients with adverse events by system organ class and preferred term
  measure: The number of patients with adverse events of special interest
  time frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
  description: Number of patients with adverse events of special interest by system organ class and preferred term
  measure: The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.
  time frame: From first dose of study drug until the end of Cycle 1
  description: A DLT is a toxicity as defined in the protocol that occurs from the first dose of study drug up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation.
  measure: The number of patients with serious adverse events
  time frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
  description: Number of patients with serious adverse events by system organ class and preferred term
  measure: Objective Response Rate (ORR)
  time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)
  description: The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose expansion only.
  measure: Objective Response Rate (ORR)
  time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)
  description: The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose escalation only.
  measure: Disease Control Rate (DCR)
  time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)
  description: Percentage of patients with confirmed complete or partial response or having stable disease maintained for >= 11 weeks from first dose, according to response criteria in solid tumours (RECIST 1.1).
  measure: Duration of response (DoR)
  time frame: From the first documented response to progressive disease or death in the absence of disease progression (approx. 2 years)
  description: The time from the date of first response until date of disease progression or death in the absence of disease progression, according to response criteria in solid tumours (RECIST 1.1).
  measure: Progression free Survival (PFS)
  time frame: From the start of study treatment/date of randomization to progressive disease or death in the absence of disease progression (approx. 2 years)
  description: The time from the start of study treatment/date of randomization until RECIST 1.1 defined disease progression or death in the absence of disease progression.
  measure: Overall Survival (OS)
  time frame: From the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)
  description: The time from the start of study treatment/date of randomization until death due to any cause.
  measure: Pharmacokinetics of AZD5863: Maximum plasma concentration of the study drug (Cmax)
  time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)
  description: Maximum observed plasma concentration of the study drug
  measure: Pharmacokinetics of AZD5863: Area Under the concentration-time curve (AUC)
  time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)
  description: Area under the plasma concentration-time curve
  measure: Pharmacokinetics of AZD5863: Clearance
  time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)
  description: A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.
  measure: Pharmacokinetics of AZD5863: Terminal elimination half-life (t 1/2)
  time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)
  description: Terminal elimination half life.
  measure: Immunogenicity of AZD5863
  time frame: From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)
  description: The number and percentage of participants who develop anti-drug antibodies (ADAs) measured in serum
  measure: Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863
  time frame: From time of Informed consent, at predefined intervals (including screening, on-treatment or end of treatment) throughout the study (over approx. 2 years)
  description: Measure CLDN18.2 expression (IHC) in baseline and/or on-treatment tumor biopsies and correlate with clinical outcome
  arm group label: Module 1: AZD5863 Monotherapy Intravenous (IV)
  arm group type: Experimental
  description: Module 1: AZD5863 Intravenous (IV) Monotherapy
  arm group label: Module 2: AZD5863 Monotherapy Subcutaneous (SC)
  arm group type: Experimental
  description: Module 2: AZD5863 Subcutaneous (SC) Monotherapy
  intervention type: Drug
  intervention name: AZD5863
  description: T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
  arm group label: Module 1: AZD5863 Monotherapy Intravenous (IV)
  arm group label: Module 2: AZD5863 Monotherapy Subcutaneous (SC)
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: AstraZeneca Clinical Study Information Center
  phone: 1-877-240-9479
  email: information.center@astrazeneca.com
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  facility: 
  status: Not yet recruiting
  country: China
  country: Japan
  country: Korea, Republic of
  country: Netherlands
  country: Taiwan
  country: United Kingdom
  country: United States
  responsible party type: Sponsor
  mesh term: Adenocarcinoma
  mesh term: Stomach Neoplasms
  sharing ipd: Yes
  ipd description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
  "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
  ipd info type: Study Protocol
  ipd info type: Statistical Analysis Plan (SAP)
  ipd time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
  ipd access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
  ipd url: https://astrazenecagroup-dt.pharmacm.com/DT/Home